Colin Rom retweetledi
I had an awesome conversation with @hubermanlab about the massive shift happening in health right now. Link below!
English
Colin Rom
126 posts
Colin Rom
@CF_Rom
policy @a16zBioHealth
Washington, DC Katılım Haziran 2014
1.3K Takip Edilen322 Takipçiler
Colin Rom retweetledi
We @a16z could not be more thrilled to lead @tryeasehealth's $41M Series A to redefine healthcare’s operating system, unifying intake (CRM), clinical (EHR), and billing (RCM) into a single, AI-native core platform.
We’ve seen this operating system playbook succeed in other industries with companies like Toast and ServiceTitan. Healthcare – long burdened by fragmented, legacy software – is ready for the same shift.
Ease is starting in behavioral health, and already supports hundreds of providers across inpatient, outpatient (IOP, PHP, MAT), and residential.
The team made this decision easy. CEO @zachcohen25 has been a friend and colleague at a16z for years, and was someone I knew I’d be extremely lucky to back if ever given the opportunity. CTO @therealarrays is an incredible engineering leader with a track record of building and scaling elite technical teams. And President Steve Gold previously built and sold the behavioral health leader Refresh to Optum for one of the largest exits in the space.
We’re proud to partner with Zach, Raymond, and Steve, and to invest alongside @AbstractVC, @BoxGroup, @seedtosunflower, and F3 Partners.
Check it out: easehealth.com
@EvaSteinman @illscience
English
Colin Rom retweetledi
what happens when the marginal cost of health information goes to zero and consumption of care explodes?
check out thoughts from @julesyoo, @JayRughani, and the a16z team below
GIF
Jay Rughani@JayRughani
English
Colin Rom retweetledi
How should care be paid for in a world of abundant supply and consumers continuously engaged with AI-powered clinicians? Hundreds of AI pricing experiments are playing out in the wild as we speak, including CMMI leading the charge through ACCESS. Looking forward to discussing the state of the state and where this is all headed with my friends Rohit Chandra of @ClevelandClinic and @AbeSutton of CMMI at ViVE. #ViVEvent
English
Colin Rom retweetledi
Biology today is fragmented across PDFs, spreadsheets, and databases. Humans stitch results together manually, often irreproducibly.
Designers got Figma. Analysts got Excel. Software engineers got IDEs. It’s time biologists get tools that reflect the way science actually works.
@phylo_bio is building the first “Integrated Biology Environment” (IBE) – a single place where hypotheses are generated, experiments are planned, data is analyzed, models are run, and results are produced in a way that’s auditable and reproducible.
Phylo’s cofounders Kexin Huang and Yuanhao Qu are the team for this problem: Kexin has spent close to a decade pursuing an “AI scientist” since before the category was defined, and Yuanhao has deep domain expertise in experimental and computational biology.
Together they built Biomni – a popular open-source biomedical research agent that became the first concrete step toward Phylo’s IBE platform. Today they’re releasing Biomni Lab, an enterprise-grade environment built on the foundation of Biomni ready for production scientific use.
We’re proud to co-lead Phylo’s $13.5M seed round and partner with a team uniquely suited to build a native environment for scientific discovery – an AI scientist built by and for scientists.
By @JorgeCondeBio and @zakdoric
@KexinHuang5 @YuanhaoQ
Kexin Huang@KexinHuang5
Today we’re launching Phylo, a research lab studying agentic biology, backed by a $13.5M seed round co-led by @a16z and @MenloVentures / Anthology Fund @AnthropicAI. We’re also introducing a research preview of Biomni Lab, the first Integrated Biology Environment (IBE), where we’re imagining a new way biologists work. Biomni Lab uses agents to orchestrate hundreds of biological databases, software tools, molecular AI models, expert workflows, and even external research services in one workspace, supporting research end-to-end from question to experiment to result. Agents handle the mechanics, while you define the question, then review, steer, and decide. Scientists end up spending more time on science: asking questions, understanding mechanisms, and eliminating diseases. Phylo (@phylo_bio) is a spin-out of @ProjectBiomni, where we will maintain the open-source community and push open-science research. I’m grateful to continue building with my co-founders @YuanhaoQ @jure @lecong and the dream founding team @serena2z @TianweiShe @huangzixin20151 @gm2123 @margaretwhua @malayhgandhi. We’re also fortunate to be advised by leading scientists @zhangf, Carolyn Bertozzi, and @fabian_theis, and supported by an amazing group of investors including @JorgeCondeBio @zakdoric Matt Kraning @ZettaVentures @dreidco @conviction @saranormous @svangel @valkyrie_vc and others. Biomni Lab is available for free today: biomni.phylo.bio Learn more in our launch post: phylo.bio/blog/company-f… We are also hosting launch events - join us at South San Francisco: luma.com/n8k8qb0n Virtual: luma.com/l5ryjaij We’re also hiring! phylo.bio/careers
English
Colin Rom retweetledi
“230 million people around the world are using ChatGPT for health related questions each week.”
a16z's Jay Rughani on why people are turning to AI for health:
“The healthcare system that we have today in the US is drastically supply constrained.”
“A hundred million people plus don’t have access to a primary care doc.”
“All that friction is frustrating, and the demand exhaust shoots off somewhere.”
“People want agency, so that agency’s gonna go somewhere.”
@JayRughani @nikillinit
Jay Rughani@JayRughani
Healthcare is off to a wild start in 2026. On the @a16z pod, I riffed with America's favorite healthcare comedian, Nikhil Krishnan of Out-Of-Pocket, to explore what else will happen: - AI doctors going mainstream - People opting out of health insurance entirely - Weight-loss drug usage doubling - Peptide parties proliferating - Healthcare labor crisis cascading - and more... Was fun to question some assumptions underlying our healthcare system and debate how to build a better one w/ @nikillinit. 00:00 Introduction 02:15 Healthcare Predictions for 2026 08:00 Taking Healthcare In Your Own Hands 26:59 Explosion of Self Monitoring 31:38 Our Desire for Agency in Healthcare 34:42 AI "Doctors" Everywhere 41:43 Clashing Regulations, IP Battles, and Populism 46:42 How will we know AI is working in Healthcare? 57:15 AI Impact on Healthcare Jobs 01:05:39 The Human vs. AI Debate in Healthcare 01:08:52 Weight Loss Drug Ubiquity 01:17:03 The Gray Market of Peptides 01:29:23 Should We Spend More on Healthcare? 01:34:29 Content Diets in the Age of AI Slop
English
Colin Rom retweetledi
Operating on DNA is more like surgery than medicine
a16z.news/p/operating-on…
Jorge Conde@JorgeCondeBio
English
Colin Rom retweetledi
Colin Rom retweetledi
thanks for having me on, @tbpn!!! ordering the horse now.
TBPN@tbpn
.@a16z's @jkhamehl shared her expectations for the 2026 IPO market: "I feel like Elon dropped an early Christmas present when it was rumored that SpaceX might be going public in 2026." "Once one breaks through, it's going to be a watershed moment that might even top 2021 in terms of the amount of liquidity coming back to folks."
English
Colin Rom retweetledi
Colin Rom retweetledi
Cures are already here -- they just aren’t evenly distributed. Aradigm is changing that.
Some of the most innovative, life-saving therapies are also the most expensive. For example, Lenmeldy, a potentially curative therapy for Metachromatic leukodystrophy (MLD), carries a list price of $4.25 million per dose, making it the most expensive therapy in the world. Lenmeldy is not an outlier: many cell & gene therapies carry million-dollar price tags for a single dose.
Given the current healthcare payment and care infrastructure, the distribution and administration of innovative, life-saving therapies is both incredibly inefficient and a terrible experience for patients and providers alike:
1. Insurance limitations: These therapies generate benefits that accrue over a lifetime, but today the price must be paid upfront
2. Patient access burden: Rounds of prior authorizations and negotiations between care providers and payors delay patient care
3. Care delivery complexity: These curative therapies are expensive to make and complex to administer, requiring heavy oversight from clinicians both pre- and post-administration
Aradigm is the infrastructure layer for the cure-based era of healthcare.
While traditional employer-sponsored plans treat these life-saving treatments as (very) expensive one-offs, Aradigm is building a care and coverage ecosystem tailor-made for these kinds of breakthroughs. By pooling risks and resources specific to these patients, Aradigm offers economies of scale, domain expertise, and an orchestration layer that traditional models lack.
Aradigm ensures patients receive efficient, high-quality access to advanced therapeutic approaches by:
1. aggregating a group of employers and insurers to effectively pool risk and reduce premiums;
2. convening a network of specialized providers and manufacturers to negotiate preferred pricing and financing, and create a shared knowledge-base for both patients and providers, alike;
3. orchestrating all stakeholders through the patient journey in a way that reduces the logistical burden of accessing, administering, and, ultimately, paying for life-saving care.
Today, we at @a16z (@julesyoo & I) are excited to congratulate Aradigm on their public launch and Series A financing led by Frist Cressey Ventures along with Morgan Health and us, after we first backed the company at inception here @a16z in 2024. William Shrank, Spencer Carrucciu, Annie Collins, Justus Ruff, & the Aradigm team are uniquely positioned to solve this gap between the fields of bio & health.
They’ve developed a first-of-its-kind platform with support of 15 of the nation’s largest employers and six leading payors. We’re proud to continue our partnership as they build the backbone that ensures important therapies are broadly accessible to patients.
The cure-based era of medicine needs new infrastructure. Aradigm is building it.
a16z.com/announcement/i…
English
Colin Rom retweetledi
Truly incredible vision and ambition to improve American lives from @HHS_Jim and his colleagues. It’s time to build health AI. 🩺👨⚕️🇺🇸🚀
Deputy Secretary Jim O'Neill@HHS_Jim
We are excited to release our AI Strategy to advance rapid AI adoption across HHS by modernizing processes, cutting red tape, and getting usable tools into the hands of our workforce. In the future, AI will help us accelerate approvals at FDA, fight fraud and improve claim adjudication at CMS, and streamline grant review across the department. The Strategy lays the foundation for HHS' role in advancing AI across the health care industry. I thank my colleagues for ushing in the next chapter of AI to support a healthier America. More to come.
English
Colin Rom retweetledi
Formation Bio CEO Ben Liu on overcoming adverse selection in clinical trials:
“No one's willingly looking to get rid of a great drug. And so the reason why we play at this IND Phase 1 translational medicine juncture is because this is where we think the markets are most dislocated today.”
“Where we play, there's oftentimes not data yet to know.”
@formationbio @BenjamineYLiu
English
Colin Rom retweetledi
Our nation is chronically ill and getting worse. ~40% of US adults live with obesity, over 2x what it was a few decades ago.
This is why we invested in @CounselHealth, a full-stack, AI-native medical group that provides unlimited guidance from real doctors, scaled by their medical AI.
Jay Rughani@JayRughani
Over 100 million people in the US are without a dedicated doctor. But it shouldn't have to be that way. The technology to scale medical advice exists today. I’m proud that @a16z is doubling down to co-lead @CounselHealth’s Series A alongside our friends at @GVteam. On top of that, Counsel's medical AI is now available to anyone. Our healthcare system is designed to ration access to our scarcest resource – doctor time. And in a world where clinician capacity is scarce, people are forced to turn to Google or ChatGPT for answers. Consumers ultimately need clinical resolution: the prescription, the lab test, the specialist appointment, the follow-up, the ongoing guidance and encouragement to change their lifestyle. Counsel is building healthcare abundance for the AI era. We led Counsel’s seed financing last year because of our conviction in this bold idea: that we can build a world in which everyone has their own doctor for life. They’ve seen immense progress under the leadership of @malagappan, who was previously a Stanford-trained physician, AI researcher, and healthtech executive. I’m delighted to expand our support as Counsel redefines how we access healthcare. @julesyoo @a16zBioHealth
English
Colin Rom retweetledi
Thank you to @realDonaldTrump for the opportunity to serve this great country. Our future as a nation is incredibly bright, and I am humbled to be able to play a small part in helping ensure this path to further greatness!
Alex Immerman@aleximm
Hell yea @skupor! The US government is lucky to have you. Make meritocracy great again.
English
Colin Rom retweetledi
Colin Rom retweetledi
"By making its model open-source, the Chinese hedge fund behind DeepSeek has confirmed how counterproductive the Biden administration’s pro-containment, pro-hegemony, anti-open source AI strategy had been.
Biden issued an executive order which sought to constrain compute under an arbitrary threshold, bar open source as an alleged threat to national security, and effectively allow regulatory capture by the biggest players. The administration and its enablers wanted to limit math, and in turn, limit code—but ended up just limiting America’s lead."
thefp.com/p/why-deepseek…
English
Colin Rom retweetledi
100 percent @JTLonsdale. The Texas bill is the result of old thinking about AI that relied too heavily on the panic mongering of the Biden admin. It needs to be dumped in the trash. Let Trump lead the way. @YouDecideHealth
Joe Lonsdale@JTLonsdale
This week, Trump cancelled Biden’s AI Reg EO and promised MASSIVE AI investment. Yet as we celebrate in DC, Texas is about to hand its AI industry to Biden bureaucrats and Big Tech: the Texas Responsible AI Governance Act (TRAIGA) would kill innovation, jobs, and let China win.
English
Colin Rom retweetledi
Colin Rom retweetledi
I am very excited to be working with the Eli Lilly team on this exciting new fund that will make it easier for founders to succeed in bio tech! @vintweeta
a16z.com/announcement-a…
English